Raymond Debbane bought $353k of LXRX
director at LEXICON PHARMACEUTICALS, INC.. 268,497 shares at an average of $1.31, traded Feb 13, 2026, filed Feb 18, 2026.
Score components
- +15RoleDirector
- +15Trade size$353k at market
- +3Relative to holdingsHoldings up 19%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +18.2%, 3m +67.4%, 6m +82.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062822-26-000029, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2026 | POpen-market purchase Common Stock | +57,952 | $1.31 | $76k | 1,443,641 | Feb 18, 2026 |
| Feb 17, 2026 | POpen-market purchase Common Stock | +76,857 | $1.31 | $101k | 1,520,498 | Feb 18, 2026 |
| Feb 18, 2026 | POpen-market purchase Common Stock | +133,688 | $1.32 | $176k | 1,654,186 | Feb 18, 2026 |
Related signals
Other insiders at LEXICON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $2,980 2,000 shares | +0% | |
| 34Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $147k 100,000 shares | +6% | |
| 35Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $220k 150,000 shares | +9% | |
| 56Moderate | LEXICON PHARMACEUTICALS, INC. | Invus Global Management, LLC director, owner | $2.0M 1,538,462 shares | - | |
| 69Notable | LEXICON PHARMACEUTICALS, INC. | Lonnel Coats Chief Executive Officer | $95k 90,000 shares | +11% | |
| 63Notable | LEXICON PHARMACEUTICALS, INC. | Philippe Amouyal director | $202k 200,000 shares | +496% | |
| 51Moderate | LEXICON PHARMACEUTICALS, INC. | Lonnel Coats Chief Executive Officer | $10k 10,000 shares | +1% | |
| 58Moderate | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $1.1M 1,000,000 shares | +293% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.